Subcutaneous Immunoglobulin (SCIg) Treatment
Cross-source consensus on Subcutaneous Immunoglobulin (SCIg) Treatment from 1 sources and 4 claims.
1 sources · 4 claims
How it works
Risks & contraindications
Comparisons
Highlighted claims
- SCIg is self-administered at home by the patient, whereas IVIg requires an outpatient clinic or hospital setting. — Benefits and challenges in everyday life for patients performing subcutaneous immunoglobulin treatment at home: a qualitative interview study
- Switching from IVIg to SCIg reconfigures the patient's role in treatment administration, alters the impact on daily life, and changes healthcare contact patterns. — Benefits and challenges in everyday life for patients performing subcutaneous immunoglobulin treatment at home: a qualitative interview study
- Changes in immunoglobulin variant, medical equipment, or dosage can temporarily destabilise established patient routines. — Benefits and challenges in everyday life for patients performing subcutaneous immunoglobulin treatment at home: a qualitative interview study
- Post-treatment physical discomfort including fluid accumulation under the skin and seepage from needle sites can limit physical activity after high-dose sessions. — Benefits and challenges in everyday life for patients performing subcutaneous immunoglobulin treatment at home: a qualitative interview study